Neutrophil activation has been identified to be a key requisite in blister formation in epidermolysis bullosa acquisita (EBA).

In our MD-project we want to stimulate human neutrophils with immune complex (IC) consisting of recombinant collagen type 7 (hCOL7) and anti hCOL-IgG 7 (hCOL7/anti hCOL7-IgG) to induce ROS release. By using a chemiluminescence based in vitro assay we are going to inhibit neutrophil ROS release by using substances of a membrane transporter/ion channel compound library.

Hopefully, we can identify new potential drugs for the treatment of EBA and other related autoimmune blistering diseases.